Dean's List: New Funding Awards

June 2024

New Federal Awards

Sarah Beattie

Pediatrics

NIH R21
2 years

HTS with Aspergillus fumigatus for novel, mold-active antifungals

Ruth Chimenti

Physical Therapy

DoD, CDMRP
4 years

Expanding and Accelerating Access to Care for Achilles Tendinopathy through Self-management Rehabilitation Strategies

Martine Dunnwald

Anatomy & Cell Biology

NSF
4 years

Formation and function of the periderm

Elissa Faro

Internal Medicine

NIH R01
5 years

Can an Evidence-Based Mental Health Intervention be Implemented into Preexisting Home Visiting Programs using Implementation Facilitation?

John Harty

Pathology

NIH R01
5 years

Brain T cell interactions in microbial experienced mice

NIH R21
2 years

Brain T cell interactions in microbial experienced mice

Christopher Petkov

Neurosurgery

NSF
4 years

Neural Mechanisms for Auditory Memory Sequencing and Prediction

Anjali Sharathkuman

Pediatrics

NIH R21
1.5 years

Epidemiology and Biosocial risk factors for adverse outcomes of COVID-19 in people with sickle cell disease : Analyses of national COVID surveillance registry

Daniel Tranel

Neurology

NIH T32
5 years

Understanding Health and Disease at the Behavioral-Biomedical Interface

Budd Tucker, Contact PI
Robert Mullins, MPI

Ophthalmology

NIH R01
4 years

Sustained Treatment of Wet AMD

Jessica Tucker

Microbiology

NIH R21
2 years

Gammaherpesviruses induce transfer RNA cleavage

Other Awards

James Byrne

Radiation Oncology

Dr. Ralph and Marian Falk Medical Research Trust

Novel materials to improve management of hypoxic tumors

Margaret Byrne

Internal Medicine

Merck & Company, Inc.

Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

Linda Cadaret

Internal Medicine

GB002, Inc.

PROSERA

Alejandro Comellas Freymond

Internal Medicine

Duke University

RECOVER-AUTONOMIC: A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Marlan Hansen, Contact PI
Matthew Howard, MPI
Samuel Young, MPI

Otolaryngology

M34 Inc.

Recombinant AAV capsid library screening to identify clinically relevant capsid variants in humans

Markus Kuehn

Opthalmology

Boehringer Ingelheim GmbH

AMPK Activation for Neuroprotection in Glaucoma

Douglas Laux

Internal Medicine

GlaxoSmithKline LLC

Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Lama Noureddine

Internal Medicine

Amgen, Inc.

Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis

Tahaunty Pena

Internal Medicine

Sanofi US Services Inc.

Oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung tr

Michael Shy

Neurology

Elpida Therapeutics SPC

A Prospective Natural History and Outcome Meausre Discovery Study of Charcot-Marie-Tooth Disease, Type 4J

Ian Thornell

Internal Medicine

Cystic Fibrosis Foundation

Cellular contributions to HEMT

Praveen Vikas

Internal Medicine

Pfizer, Inc.

PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE  ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR BASED THERAPY

Michael Wendt

Internal Medicine

Novartis Pharmaceuticals Corporation

Impact of Hypoxia on Lipid Metabolism in Obesity-Driven Breast Cancer Progression

Hanna Zembrzuska

Internal Medicine

Novartis Pharmaceuticals Corporation

Intravenous secukinumab infusion in adults with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR).

May 2024

New Federal Awards

Barry London, Contact PI
Bryan Allen, MPI

Internal Medicine

NIH U01
3 years

Sex-dependent Impairment of Nitric Oxide Signaling and Mitochondrial Metabolism in Radiation-Induced Cardio-Pulmonary Dysfunction

Vincent Magnotta, Contact PI
Jacob Mathews, MPI

Radiology

NIH R01
5 years

High Resolution MRSI for Alzheimer's Disease and Related Dementias

Maria Spies

Biochemistry

NIH T32
5 years

Iowa Biotech-TP: Predoctoral Program in Biotechnology

Colette Galet

Emergency Medicine

DHHS, Administration on Aging
3 years

Empowering Communities to Deliver and Sustain Evidence-Based Falls Prevention Programs

Hua Sun

Pediatrics

NIH R01
5 years

Targeting dynein-mediated trafficking in diabetic podocytopathy

Rebecca Dodd

Internal Medicine

Dod, CDMRP
3 years

Targeted Therapy for MPNST Metastasis

Competitive Renewal

Vanessa Curtis, Contact PI
Thomas Scholz, MPI

Pediatrics

Iowa DHHS
1 year

Pediatric Mental Health Care Access Program (PMHCAP)

Other Awards

Carol Johnson

Pediatrics

Iowa DHHS
5 years

Iowa Newborn Screening (NBS) Propel Project

Grerk Sutamtewagul

Internal Medicine

Kura Oncology
3 years

Venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

Kura Oncology
3 years

 Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Douglas Laux

Internal Medicine

Regeneron Pharmaceuticals, Inc.
3 years

REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with Cemiplimab in patients with advanced solid tumors.

David Bender

OBGyN

GOG Foundation
5 years

NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer

GOG Foundation
3 years

VB10.16 Alone or in Combination with Atezolizumab in Patients with HPV16-Positive, PD-L1-positive, Recurrent or Metastatic Cervical Cancer who are Refractory to Pembrolizumab with Chemotherapy with/without Bevacizumab

Sam Stephens

Internal Medicine

Juvenile Diabetes Research Foundation International
3 years

201311107-FY24 SRA: Role of -cell Golgi dysfunction in Type 1 diabetes pathogenesis

Christopher Strouse

Internal Medicine

Janssen Research and Development, LLC
2.5 years

Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma

April 2024

New Federal Awards

Jing Jiang

Pediatrics

NIH R01
5 years

Mapping a Causal Prefrontal Pathway for Amygdala Modulation Utilizing Invasive and Noninvasive Brain Stimulation and Recording Methods in Humans

Marco Hefti

Pathology

NIH R01
5 years

A non-canonical role for tau in early human brain development

Budd Tucker

Ophthalmology

NIH R21
2 years

Label-free microfluidic isolation of patient iPSC-derived photoreceptor cells

Steven Offer

Pathology

NIH R01
2 years

A precision medicine approach to improve prediction of severe toxicity in fluorouracil chemotherapy

Competitive Renewals

George Richerson

Neruology

NIH R01
5 years

Inhibition of central CO2 chemoreception by seizures: Effects on ventilation, cardiovascular control and postictal recovery of consciousness

Other Awards

Alejandro Comellas Freymond

Internal Medicine

KUMC
5 years

All of Us Research Program - Heartland Consortium

Erin Shriver

Ophthalmology

Immunovant Sciences, GmbH
5 years

Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)

Yousef Zakharia

Internal Medicine

Astellas Pharma Global Development, Inc
3 years

Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)

Hanna Zembrzuska

Internal Medicine

ImmPACT Bio USA, Inc.
3 years

IMPT-514 in participants with active, refractory lupus nephritis and systemic lupus erythematosus

David Bushnell

Radiology

RayzeBio, Inc.
5 years

RYZ101 in combination with carboplatin + etoposide + atezolizumab in subjects with somatostatin receptor expressing (SSTR+) extensive stage small cell lung cancer (ES-SCLC)

Christopher Strouse

Internal Medicine

Janssen Research & Development, Inc
5 years

JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma

Tracey Cho

Neurology

Sanofi US Services, Inc
5 years

Frexalimab (SAR441344) to Terifluomide (Aubagio) in Adult Participants with Relapsing Forms of Multiple Sclerosis

Sanofi US Services, Inc
5 years

Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis

Katherine Mathews

Pediatrics

Avidity Biosciences, Inc
5 years

AOC 1044 Administered Intravenously to Healthy Adults

Val Sheffield

Pediatrics

CRISPR Therapeutics, Inc
2 years

MYOC gene editing for Myocilin Associated Glaucoma

March 2024

New Federal Awards

Sandra Blom

Internal Medicine

NIH F31
3 years

GRASP55 Regulates Pancreatic Beta-cell Golgi Structure and Function During Cytokine Stress

Songhai Chen, Contact PI
Ronald Wiegel, MPI

Neuroscience & Pharmacology

NIH R01
5 years

Role of the CTLH E3 ubiquitin ligase in breast cancer progression

Carl Andrew Frank

Anatomy & Cell Biology

NIH R01
5 years

Synaptic defects caused by Mitochondrial Complex I dysfunction

Stephanie Gantz

Physiology

NIH R01
5 years

Regulation of monoamine neurons by delta glutamate receptors

Lyndsay Harshman

Pediatrics

DoD, CDMRP
2 years

Women's Health in Tuberous Sclerosis Complex: A Population Based Assessment of Morbidity to Inform Clinical Care

Miriam McDonough

Neuroscience & Pharmacology

NIH F31
3 years

Investigating the molecular mechanisms underlying aldosterone-mediated sodium appetite

Scott Moye-Rowley

Physiology

NIH R21
2 years

Novel mechanisms of azole resistance in clinical isolates of Candida glabrata

Krystal Parker

Psychiatry

NIH R21
2 years

Roles of Descending Forebrain Pathways to the Cerebellum in Behavioral Timing

Mark Schultz

Pediatrics

NIH R03
2 years

Investigating the importance of liver-specific glycans on NPC1 proteostasis

Hanna Stevens

Psychiatry

NIH R01
3 years

Adolescent Insecticide Exposure and ADHD Risk: Mechanisms of Immediate Effects and Ongoing Vulnerability

Stefan Strack

Neuroscience & Pharmacology

DoD, CDMRP
2 years

Identifying temporal and spatial origins and reversibility in mouse models of neurodevelopmental disorders with autism

Ajit Vikram

Internal Medicine

NIH R01
5 years

Glycopeptide vancomycin reshapes gut microbiota to mediate cardioprotective effects via microRNA-204

Jason Wilken

Physical Therapy

DoD, CDMRP
2 years

The Effects of Heel Clearance on Foot Loading with Carbon Fiber Custom Dynamic Orthoses

Competitive Renewals

Julien Sebag

Physiology

NIH R01
4 years

Investigating the requirement of MRAP2 for ghrelin function

Maria Spies

Biochemistry

NIH R35
5 years

Assembly and Dynamics of Molecular Machines in Genome Maintenance

Other Awards

John Bernat

Pediatrics

Denali Therapeutics
5 years

DNL126 in pediatric participants with mucopolysaccharidosis type IIIA (Sanfilippo Syndrome Type A)

Marina Del Rios, Contact PI
Kari Harland, MPI

Emergency Medicine

Robert Wood Johnson Foundation

2 years

Innovation and Measurement of Pre-emptive Action on Racial Justice and Health Equity Curriculum Teaching (IMPACT)

Mohammed Milhem

Internal Medicine

Polaris Pharmaceuticals, Inc.
5 years

Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial

Antonio Sanchez

Internal Medicine

GlaxoSmithKline, Inc.
3 years

GSK4532990   in   Adults   with pre-cirrhotic Non-Alcoholic Steatohepatitis (NASH)

Lane Strathearn

Pediatrics

EarliTec Diagnostics, Inc.
5 years

Dynamic Quantification of Social-Visual Engagement (DQSVE) in Autism Spectrum Disorder (ASD): Diagnosis and Assessment For Children Ages 31 - 84 Months.

Christopher Strouse

Internal Medicine

Juno Therapeutics, Inc.
4 years

BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma

Grerk Sutatewagul

Internal Medicine

Merk Sharp & Dohme, LLC
5 years

Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

Tomohiro Tanaka

Internal Medicine

Takeda Development Center Americas, Inc.
5 years

Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis

Budd Tucker

Ophthalmology

Gilbert Famiy Foundation
3 years

Development of novel next generation model systems for study and treatment of NF1

Yousef Zakharia

Internal Medicine

Arsenal Biosciences
3 years

AB-2100 in patients with recurrent advanced or metastatic clear-cell renal cell carcinoma.

February 2024

New Federal Awards          

Michael Anderson, Contact PI
Todd Scheetz, MPI
John Fingert, MPI

Physiology,
Ophthalmology

NIH R01
4 years

Foundational Biology of Glaucoma GWAS Loci

Denice Hodgson-Zingman, Contact PI
Leonid Zingman, MPI

Internal Medicine

NIH R01
5 years

A New Pacing Approach for Cardiac Conditioning and Enhanced Cardioprotection

Emily Adelizzi

Anatomy & Cell Biology

NIH F31
3 years

Deciphering a tissue specific role for Arhgap29 during palatogenesis

Damian Krysan

Pediatrics

NIH R01
5 years

REgulation of Candida albicans Pathogenesis by Protein Kinase and Transccription Factor

Sarah Short

Internal Medicine

NIH K01
5 years

Antioxidant regulation of intestinal homeostasis and disease

Other Awards

Don Andrson

Orthopedic Surgery

Arthritis Foundation
2 years

Determining the traumatic origins of ankle OA and the time to joint degeneration

Tracey Cho

Neurology

Genetech, Inc.
5 years

Satralizumab in patients with anti-n-methyl D aspartic acid receptor (NMDAR) or anti-leucine rich glioma inactivated 1 (LGI1)

Prajwal Dhakal

Internal Medicine

Nerviano Medical Sciences, S.r.l.
3 years

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML

Douglas Laux

Internal Medicine

Hoosier Cancer Research Network, Inc.
3 years

A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (HCRN MCC20-443; iPRRT Study)

Melinda Seering

Anesthesia

Haisco-USA Pharmaceuticals, Inc.
5 years

A Global Multicenter, Randomized, Double-blinded, Propofol controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery

Saima Sharif

Internal Medicine

PDD Investigator Services, LLC
3 years

A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer

January 2024

New Fedaral Awards:

Patrick Sinn, Contact PI

Paul McCray, MPI

Pediatrics

NIH R01
​4 years

Adenine Base Edited Correction of Cystic Fibrosis Airways

Lane Strathearn

Pediatrics

NIH R01
4.5 years

Perinatal Experience and Epigenetic Change in Autism: Discovering Modifiable Pathways for Intervention

Michael Tomasson

Internal Medicine

US National Science Foundation
1 year

I-Corps: A Home-based Solution for Remote Lung Function Monitoring for Patients with Chronic Lung Disease

Other Awards:

Ted Abel

Neuroscience & Pharmacology

Eagles Autism Foundation 
2 years

Characterizing the functional impact of mutations in Nr4a2-related Neurodevelopmental Syndrome

Huxing Cui

Novo Nordisk Pharmaceuticals, Inc

Novo Nordisk Pharmaceuticals, Inc
2 years

Neural basis of metabolic control by ciliary cAMP signaling

Alina Dumitrescu

Ophthalmology

Janssen Research & Development, Inc.
8 years

Global Patient Registry of Inherited Retinal Diseases

Rami El Abiad

Internal Medicine

Sanofi US Services Inc.
3 years

Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants with Eosinophilic Esophagitis (EoE)

Umar Farooq

Internal Medicine

Janssen Research & Development, Inc. 
3 years

Global Patient Registry of Inherited Retinal Diseases

Mark Granner

Neurology

Neurona Therapeutics, Inc
4 years

A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Jon Houtman

Microbiology

Roy J. Carver Charitable Trust
1 year

State-of-the-art multicolor cellscape imaging system by canopy biosciences.

Asad Javed

Internal Medicine

IDEAYA Biosciences Inc.
5 years

IDE196 (Darovasertib) in combination with Crizotinib versus investigator's choice of treatment as a first-line therapy in HLA-A2 negative metastatic uveal melanoma (DAR-UM-2)

Douglas Laux

Internal Medicine

Regeneron Pharmaceuticals, Inc.
5 years

A multicenter, open-label phase 2 study of intratumoral vidutolimod (CMP-001) in combination with inravenous cemiplimabin subjects with selected types of advanced or metastatic cancer.

Paul McCray

Pediatrics

Cystic Fibrosis Foundation
2 years

005651G223 Adenine Base Editing Repair of a CFTR Nonsense Mutation

Mohammed Milhem

Internal Medicine

Merck Sharp & Dohme LLC
8 years

Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma

Dawn Quelle, Contact PI
Rebecca Dodd, MPI 

Neuroscience & Pharmacology,
Internal Medicine

Gilbert Family Foundation
3 years

Improving Immunotherapy in MPNSTs

Ziying Yan

Anatomy & Cell Biology

Cystic Fibrosis Foundation
2 years

Developing Basal Cell Tropic Human Bocavirus for Applications in Airway Gene Editing

Yousef Zakharia

Internal Medicine

Bristol-Myers Squibb Company
5 years

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors

December 2023

New Federal Awards:

Sanjana Dayal

Internal Medicine

NIH R01
4 years

Preventive mechanisms of Age-associated Thrombosis

John Fingert, Contact PI
Todd Scheetz, MPI
Budd Tucker, MPI

Ophthalmology

NIH R21
2 years

Stem cell approaches to normal tension glaucoma

Robert Piper, Contact PI
Chris Anern, MPI

Physiology

NIH R33
2 years

Towards systematic analysis of cardiac voltage-gated sodium channel beta subunit Function

Eric Taylor

Physiology

NIH R01
4 years

Regulation of Hepatic Fuel Fluxes by the Mitochondrial Dicarboxylate Carrier

Mary Weber

Microbiology

NIH R61
3 years

Development of genetic tools for overexpression and targeted mutagenesis of Orientia tsutsugamushi TPR proteins

Competitive Awards:

Enrique Leira

Neurology

NIH U24
5 years

The University of Iowa's Regional Stroke Research Network

Other Awards:

Stephanie Chen

Pathology

Exact Sciences Corporation
3 years

Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer

Nabeel Hamzeh

Internal Medicine

Bristol-Myers Squibb Company
3 years

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the  Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

Markus Kuehn

Ophthamology

Animal Eye Consultants of Iowa
2 years

Adaptive Immune Responses Contributing to Canine Glaucoma

Delwyn Miller

Psychiatry

University of Southern California
5 years

Alzheimer's Disease Neuroimaging Initiative (ADNI4)

Amy Ryan

Anatomy and Cell Biology

Children's Hospital of Los Angeles
1 year

Development of a model that integrates inflammation and tissue injury to predict and mitigate the post-acute sequelae of COVID-19

Michael willey

Orthopedics

MEND Nutrition, Inc.
3 years

MENDTM Clinical Trial Proposal

November 2023

New Federal Awards:

Top of Page

Yi Huang

Internal Medicine

NIH R01
3 years

Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response

Competitive Awards:

Stanley Perlman

Microbiology

NIH R01
5 years

Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response

Other Awards:

Umar Farooq

Internal Medicine

Cargo Therapeutics
5 years

An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CART-cell

Umar Farooq

Internal Medicine

Janssen Research & Development, Inc.
4 years

A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non- Hodgkin Lymphoma

Philip Gander, Contact PI
Joel Berger MPI

Radiology, Neurosurgery

REAM Foundation,
2 years

Novel Investigation of Brain Mechanisms for Different Triggers in Misophonia

Dilek Ince

Internal Medicine

Corixa Corporation
3 years

A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (50 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses an

Annie Killoran

Nurology

Genetech, Inc.
3 years

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study To Evaluate The Safety, Biomarkers, And Efficacy Of Tominersen In Individuals With Prodromal And Early Manifest Huntington's Disease

Douglas Laux

Internal Medicine

Replimune, Ltd.
3 years

A Phase 2, Open-label, Multicenter Study Investigating RP3 in Combination with Other Therapy in Patients with Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Douglas Laux

Internal Medicine

Seagen, Inc.
3 years

A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors

Mohammed Milhem

Internal Medicine

Seagen, Inc.
3 years

A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors

Sneha Phadke

Internal Medicine

AstraZeneca Pharmaceuticals LP
3 years

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/

Chen Tan

Internal Medicine

Ansun Biopharma, Inc.
3 years

A Phase III Randomized Placebo-Controlled Study to Examine  the Efficacy and Safety of DAS 181 for the Treatment of Lower Respiratory Tract  Parain:fluenza Infection in Immunocompromised Subjects

Yousef Zakharia

Internal Medicine

Worldwide Clinical Trials, Inc.
3 years

A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM -RESISTANT OVARIAN CARCINOMA, ENDOMETRIAL ADENOCARCINOMA, AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS

October 2023

New Federal Awards:

Top of Page

James Byrne

Radiation Oncology

NIH K08
5 years

Exploiting Carbon Monoxide Biofoams to Radio-Sensitize Rectal Cancer Cells While Protecting Normal Bowel

Grace Ciampa

Internal Medicine

NIH F31
2 years

Examining the Function of a Novel Protein in the Cardiac Junctional Membrane Complex

Competitive Awards:

Thomas Scholz

Pediatrics

Iowa Department of Human Services 
1 year

MHDS 24-008 Community Circle of Care

Kirill Nourski

Neurosurgery

University of Wisconsin-Madison 
4 years

Mechanisms of  Loss, Recovery and Disorders of Consciousness

Other Awards:

Ernesto Ruiz Duque

Internal Medicine

Bristol-Myers Squibb Company
3 years

DISCOVER-HCM

Rami El Abiad

Internal Medicine

Celldex Therapeutics, Inc.

3 years

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis

Andrew Russo

Molecular Physics & Biophysicis

Seattle Institute for Biomedical and Clinical Research
5 years

Role of Sleep Disruption after mTBI as a Driver of Chronic Post-Traumatic Headache

Alejandro Comellas Freymond

Internal Medicine

IQVIA RDS Inc.
​3 years

A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm  Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory  Chronic Cough, Including Unexplained Chronic Cough (CALM-1)

Muhammad Furqan

Internal Medicine

AbbVie, Inc.
3 years

A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors.

Muhammad Furqan

Internal Medicine

BeiGene USA
3 years

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

Muhammad Furqan

Internal Medicine

Poseida Therapeutics, Inc.
3 years

A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF P-MUC1C-ALLO1 IN ADULT SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

David Axelrod

Surgery

CTI Clinical Trial Services, Inc.
3 years

An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA 99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standa

Sneha Phadke

Internal Medicine

NSABP Foundation, Inc.
5 years

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or

Carla Nester

Pediatrics

Apellis Pharmaceuticals, Inc.
3 years

AN OPEN-LABEL, NONRANDOMIZED, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN IN PARTICIPANTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

Patrick Sinn

Pediatrics

Cystic Fibrosis Foundation
2 years

005661G223 Base-Editing for Life-Long Correction of CF Airways

Vishnu Mani

Surgery

Direct Biologics, LLC
3 years

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized  Patients with Moderate-to-Severe ARDS: A Phase III Clinical Trial

Eric Hoffman

Radiology

Imperial College London
2 years

THE BLF EARLY COPD DEVELOPMENT PARTNERSHIP GRANT

Brian Link

Internal Medicine

Mayo Clinic
3 years

Characteristics and outcomes of patients with Diffuse Large B-cell Lymphoma Receiving Frontline Treatment at Cancer Centers within the LEO Cohort, ML43785

September 2023

New Federal Awards:

Top of Page

John Fingert, Contact PI
Todd Scheetz, MPI

Ophthalmology

NIH R01
5 years

Genetic Factors for Glaucoma in the OHTS; Risk, Progression and Mechanism

Aloysius Klingelhutz

Microbiology

NIH R21
2 years

The role of ISG15 and ISGylation in the senescence-associated secretory phenotype

Elizabeth Newell

Pediatrics

NIH R01
5 years

Mechanisms of type I interferon neuropathology following traumatic brain injury

Jon Houtman

Microbiology

NIH R25
5 years

R25 YES: Cancer Research Opportunities at Iowa

Competitive Awards:

Milan Sonka, Contact PI
John Buatti, MPI

Radiation Oncology

NIH R56
1 year

Deep LOGISMOS

Vincent Magnotta, Contact PI
John Wemmie, MPI

Radiology,
Psychiatry

NIH R01
5 years

Cerebellar metabolism, neural circuits, and symptoms in bipolar disorder

Other Awards:

Umar Farooq

Internal Medicine

Angiocrine Bioscience, Inc.
3 years

Angiocrine Long Term Follow-Up Umbrella Study

Umar Farooq

Internal Medicine

Nektar Therapeutics
3 years

A PHASE 2/3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NKTR-255 VS PLACEBO FOLLOWING CD19-DIRECTED CAR-T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

Bruce Gantz

Otolaryngology

Cochlear Americas
3 years

Preliminary Evaluation of a Dexamethasone Eluting Electrode Array

Marlan Hansen

Otolaryngology

Julius Clinical Research B.V.
3 years

A Natural History Study in Individuals with Otoferlin Gene  (OTOF)-Mediated Hearing Loss

Annie Killoran

Neurology

Worldwide Clinical Trials, Inc.
3 years

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (G

Antonio Sanchez

Internal Medicine

Merck Sharp & Dohme LLC
3 years

A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis

Antonio Sanchez

Internal Medicine

PPD Investigator Services, LLC
3 years

A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Christopher Strouse

Internal Medicine

Poseida Therapeutics, Inc.
3 years

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM)

August 2023

New Federal Award:

Top of Page

Alexander Boyden

Pathology

NIH R01
5 years

Pathogenic B cell:CD4 T cell interactions in a novel B cell-dependent EAE mouse model of multiple sclerosis

Sean Fain

Radiology

NIH R01
5 years

Dynamic Imaging of Lung Ventilation and Perfusion Using CT and MRI

Gena Ghearing

Neurology

CDC
5 years

Expanding epilepsy self-management support in healthcare networks (EXPAND)

Aleksander Lenert

Internal Medicine

NIH K23
3 years

Investigating Disease Activity, Bone Damage and Interleukin-1 Genes in Adult SAPHO Syndrome and Chronic Nonbacterial Osteomyelitis 

Yi Luo

Urology

DOD, CDMRP
4 years

CP220038 - Development of a novel DNA aptamer-based IFN-y targeted therapy for chronic cystitis pain

Wendy Maury, Contact PI
Noah Butler, MPI

Microbiology

NIH UH2
2 years

Defining the effect of Plasmodium infection on Ebola virus vaccine efficacy

Ben Miskle

Pharmacy Practice and Science
(Award in Psychiatry)

SAMHSA H79
5 years

Iowa Naloxone Expansion and Training (IA-NEXT)

Catherina Pinnaro

Pediatrics

NIH K23
3 years

Hyperglycemia in Turner syndrome: Mechanisms and X chromosome contributions

Matthew Potthoff

Neuroscience & Pharmacology

NIH R01
5 years

Therapeutic Potential of FGF21 for Alzheimer's Disease 

Brett Faine, Contact PI
David Talan, MPI

Emergency Medicine

NIH R21
2 years

Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial

Seth Tomchik

Neuroscience & Pharmacology

NIH R01
2 years

Dopaminergic circuit modulation of learning and arousal-mediated memory enhancement

Elliott Sohn, Contact PI
Jon Houtman, MPI
Milan Sonka, MPI

Ophthalmology,
Microbiology,
Electrical & Computer Engineering

NIH R01
4 years

MMP-9 based immune-driven mechanisms of neovascular AMD

Competitive Awards:

Marlan Hansen, Contact PI
C. Guymon, MPI

Otolaryngology

NIH R01
5 years

Reduction of Intracochlear Trauma and Fibrosis Using Dual Network, Zwitterionic Hydrogel Thin Films on Cochlear Implant Surfaces

Robert Mullins, Contact PI
Budd Tucker, MPI

Ophthlamology

NIH R01
4 years

Choriocapillaris Protection and Replacement in AMD

Other Awards:

David Bender

OBGyn

GOG Foundation
3 years

Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube,

James Byrne

Radiation Oncology

V Foundation for Cancer Research
3 years

Overcoming immunotherapy resistance using oxygen-entrapping materials

Marcelo Correia

Internal Medicine

Lilly USA, LLC
3 years

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

Umar Farooq

Internal Medicine

ImmPACT Bio USA Inc.
3 years

A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IMPT-314, A CD19/20 BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA

Muhammad Furqan

Internal Medicine

AGRESSIVE B-CELL NON HODGKIN LYMPHOMA
3 years

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304)

Muhammad Furqan

Internal Medicine

Elicio Therapeutics, Inc.
3 years

First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Solid Tumors

Hillel Haim

Microbiology

ViiV Healthcare
5 years

Computational platform to personalize Fostemsavir treatment to people living with HIV-1 

Asad Javed

Internal Medicine

Lyell Immunopharma, Inc. 
3 years

A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies

Mohammed Milhem

Internal Medicine

Merck Sharp & Dohme LLC
8 years

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE- 010)

Sneha Phadke

Internal Medicine

Arvinas Estrogen Receptor Inc.
3 years

An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting

Philip Polgreen

Internal Medicine

Pfizer, Inc
4 months

Developing approaches to estimate a more accurate measure of the burden of influenza

Ernesto Ruiz Duque

Internal Medicine

Bristol-Myers Squibb Company
3 years

ODYSSEY-HCM

Lucy Wibbenmeyer

Surgery

PolyNovo Biomaterials Pty Ltd.
3 years

Pivotal Study to Assess the Safety and Effectiveness of NovoSorb Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries

July 2023

New Federal Awards:

Top of Page

Alexandra Bova

Neurology

NIH F32
1 year

Nigrostriatal dopamine mechanisms of cognitive control

Martine Dunnwald

Anatomy & Cell Biology

NIH R03
1 year

Popliteal Pterygium syndrome, IRf6, and the periderm

Adam Dupuy

Anatomy & Cell Biology

US DoD, CDMRP
HT9425-23-1-0780
3 years

ME220036 Identification of genetic mechanisms driving transition of benign nevi to malignant melanoma

Oliver Gramlich

Ophthlamology

NIH R03
5 years

Targeting Cholesterol Homeostasis to maintain vision in MS-like optic neuritis

Xiaoyang Hua

Otolaryngology

NIH R01
5 years

The nose-lung cross talk in upper respiratory virus infection induced asthma exacerbations

Miles Pufall

Biochemistry & Molecular Biology

US National Science Foundation
2324615
3 years

NSF/MCB-BSF: The effect of transcription factor binding on UV lesion accumulations

Chen Tan

Internal Medicine

NIH R01
2 years

NK cell responses to JC polyomavirus

Tomohiro Tanaka

Internal Medicine

US DoD, CDMRP
k08
5 years

Estimating the Causal Effect of Liver Allocation Policy Reflecting the Heterogeneity from Age and Geography

Kristina Thiel

OBGyn

US DoD, CDMRP
HT9425-23-1-0744
4 years

CA220729P1 - Progestin therapy for endometrial cancer

Other Awards:

Loreen Herwaldt

Internal Medicine

University of Wisconsin-Madison
2 years

Povidone-iodine to Stop Access-Related Infections and Transmission of Staphylococcus Aureus (PAINTS)

Katie Larson Ode

Pediatrics

Worldwide Clinical Trials, Inc.
3 years

A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and  Safety of Setmelanotide in Patients with Acquired Hypothalamic Obesity

Kelly Mulfaul

Ophthalmology

BrightFocus Foundation
3 years

Investigating Human Choroidal Macrophage Recruitment and Activation in Age-related Macular Degeneration - Mulfaul 2022 - BrightFocus

Sneha Phadke

Internal Medicine

Olema Pharmaceuticals, Inc.
3 years

A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer

Donna Santillan, Contact PI
Mark santillan, MPI

OBGyn

Heartland Health Research Alliance, LTD
3 years

Heartland

Tomohiro Tanaka

Internal Medicine

PPD Investigator Services, LLC
3 years

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1)

George Weiner

Internal Medicine

V Foundation for Cancer Research
4 years

T cell help and resistance to anti-cancer monoclonal antibody therapy

Yousef Zakharia

Internal Medicine

Astellas Pharma Global Development, Inc.
3 years

A Phase 1 Study of ASP1002 in Participants with Metastatic or Locally Advanced Solid Tumors

Yousef Zakharia

Internal Medicine

AstraZeneca LP
3 years

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients I

June 2023

New Federal Awards:

Top of Page

Marina Del Rios

Emergency Medicine

NIH R01
4 years

Dime la VerDAD - Verify, Debunk, and Disseminate

Joel Geerling

Neurology

NIH R01
5 years

Brainstem cold-defense circuitry

Corinne Griguer

Radiation Oncology

NIH R01
5 years

Mitochondria electron transport chain complexes adaptative responses to cellular stress

John Harty

Pathology

NIH R21
2 years

Regulating Pathogen-induced Protective and Pathogenic CD8 T cells in the CNS

Diana Jalal, Contact PI
Richard Smith, MPI

Internal Medicine,
Otolaryngology

NIH R01
5 years

The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD

Benjamin Kelvington

Neuroscience & Pharmacology

NIH F31
3 years

Defining the molecular impact of 16p11.2 deletion on reward response in striatal dopamine receptor D1-expressing neurons

Scott Lieberman

Pediatrics

NIH R01
5 years

Tyk2 and Associated Cytokines in Salivary Gland Autoimmunity

Allison Momany

Pediatrics

NIH K99
2 years

Neonatal Stress in Very Preterm Infants: Longitudinal Effects on Epigenetics and Neurodevelopment 

Andrew Sullivan

Neuroscience & Pharmacology

NIH F31
3 years

The Role of IRX3 Neurons in the Regulation of Body Weight Homeostasis

Other Awards:

Ted Abel

Neuroscience & Pharmacology

George Mason University
5 years

Estradiol signaling pathways mediating sex differences in striatal synaptic plasticity

Sabarish Ayyappan

Internal Medicine

Mayo Clinic
3 years

Randomized phase 2 study with safety run-in of PD-1 inhibitor and IgG4 SIRP-Fc fusion protein (TTI-622) and PD-1 inhibitor and IgG1 SIRP-Fc fusion protein (TTI-621) in relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Chandrikha Chandrasekharan

Internal Medicine

Astellas Pharma, Inc
3 years

A Phase 1/1b study of ASP2074 in participants with Metastatic or Locally Advanced solid tumors

Rami El Abiad

Internal Medicine

Ellodi Pharmaceuticals, L.P.
3 years

Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, followed by a Single-arm Open-label Extension, in Adult Subjects with Eosinophilic 

Muhammad Furqan

Internal Medicine

Tempus Labs, Inc.
3 years

TEMPUS GEMINI NSCLC SURVEILLANCE STUDY

Jeremy Greenlee

Neurosurgery

Massachusetts Eye & Ear Infirmary

Next-generation clinical phenotyping and pathophysiology of laryngeal dystonia and voice tremor, Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor (Project 3)

Serena Gumusoglu

OBGyn

Burroughs Wellcome Fund
4 years

Next Gen Pregnancy Initiative

Patrick McGonagill

Surgery

CSL Behring LLC
3 years

CSL Behring TAP Study

Jacob Michaelson

Psychiatry

Columbia University
1 year

Triangulation of missense variant impact through multimodal modeling and functional assays

Sneha Phadke

Internal Medicine

PSI Pharma Support America, Inc.
3 years

An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer (ELECTRA)

Andrea Swenson

Neurology

Massachusetts General Hospital
2 years

An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis

Richard Tyler

Otolaryngology

Sage Therapeutics, Inc.
3 years

AN OPEN-LABEL STUDY EVALUATING THE SAFETY,  TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF  BREXANOLONE IN THE TREATMENT OF ADULT  PARTICIPANTS WITH TINNITUS

May 2023

New Federal Awards:

Top of Page

Bryan Allan, Contact PI
John Buatti, MPI

Radiation Oncology

NIH R21
2 years

Redox manipulation of iron to improve glioblastoma therapy: A phase 1 trial

Polly Ferguson, Contact PI
Alaxander Bassuk, MPI

Pediatrics

NIH K12
5 years

CTSA K12 PROGRAM AT THE UNIVERSITY OF IOWA

Donna Santillan

ObGyn

NIH R25
5 years

Beginning and Early Stage Translational (BEST) Researchers

Seth Tomchik

Neuroscience & Pharmacology

NIH R01
1 year

Mechanisms of Nf1 Pathophysiology Underlying Hyperactivity

Ergun Uc, Contact PI
Nandakumar Narayanan, MPI
Soura Dasgupta, MPI

Neurology,
Electrical & Computer Engineering

NIH RF1
3 years

Linear predictive coding of EEG Activity for Diagnosis of Parkinson's Disease (LEAD-PD)

Competitive Awards:

Bruce Gantz

Otolaryngology

NIH P50
5 years

Iowa Cochlear Implant Clinical Research Center VIII

Other Awards:

Chandrikha Chandrasekharan

Internal Medicine

Pharmaceutical Research Associates
3 years

A randomised, open-label, Phase II, dose/schedule optimisation study of NUC-3373/leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with previously treated...

Alicia Gerke

Internal Medicine

Merck Sharp & Doheme LLC
3 years

INSIGNIA-COPD

Marlan Hansen

Otolaryngology

Akouos, Inc
3 years

A Phase 1/2 Trial of AAVAnc80-hOTOF Gene Therapy in Individuals with  Sensorineural Hearing Loss due to Biallelic Otoferlin Gene (OTOF) Mutations

Tahaunty Pena

Internal Medicine

Renovion, Inc.
3 years

A Phase 3 Open-Label, Randomized, Standard of Care-controlled Parallel Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) Progression in Participants with Bilateral Lung Tr

Andrea Swenson

Neurology

Massachusetts General Hospital
3 years

HEALEY ALS Platform Trial, Task 12

Michael Tomasson

Internal Medicine

Pfizer, Inc.
3 years

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

Douglas Van Daele

Otolaryngology

Nyxoah SA
3 years

ACCCESS Study - A multicenter study to assess the safety and effectiveness of the Genio dual-sided hypoglossal  nerve stimulation system for the treatment of obstructive sleep apnea in subjects with complete concentric collapse of the soft palate.

Patricia Winokur

Internal Medicine

Pfizer, Inc
3 years

A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE

April 2023

New Federal Awards:

Top of Page

Mahmoud Abou Alaiwa

Internal Medicine

NIH R01
5 years

Contribution of Small Airways to Mucociliary Transport Dysfunction

Hillel Haim

Microbiology

NIH R01
4 years

Predicting HIV-1 escape from therapeutics in vitro and in vivo - toward personalizing medicine for people living with HIV

Vincent Magnotta

Radiology

NIH S10
1 year

University of Iowa - 7T Small Animal MRI Upgrade

Robert Roghair

Pediatrics

NIH R01
5 years

Sedentary behavior, physical activity, and 24-hour behavior in pregnancy and offspring health: the Pregnancy 24/7 Offspring Study

Robert Roghair

Pediatrics

NIH T35
5 years

Iowa Medical Student Summer Research Program in trans-NIDDK Research

Seth Tomchik

Neuroscience & Pharmacology

NIH R01
4 years

Genetic and molecular mechanisms of Nf1-dependent neuronal regulation of metabolism

Aislinn Williams

Psychiatry

Dod, CDMRP
3 years

AR220030_Validating tRNA viruses to target SCN2A-related autism phenotypes

Competitive Awards:

Tarah Colaizy

Pediatrics

NIH UG1
7 years

NICHD Cooperative Multicenter Neonatal Research Network

Peggy Nopoulos, Contact PI
John Wemmie, MPI

Psychiatry

NIH T32
5 years

The Iowa Neuroscience Specialty Program in Research Education (INSPIRE)

Patrick Sinn

Pediatrics

NIH R01
4 years

Life-long phenotypic correction of CF airways

Other Awards:

Sabarish Ayyappan

Internal Medicine

Kite Pharma, Inc.
5 years

A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25)

Chandrikha Chandrasekharan

Internal Medicine

Pfizer, Inc.
3 years

A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE

Umar Farooq

Internal Medicine

Kure.ai
3 years

CASE2422 A phase 1 single arm, open label study to evaluate the safety of UF-KURE19 cells in patients with relapsed or refractory B cell non-Hodgkin lymphomas.

Muhammad Furqan

Internal Medicine

AstraZeneca Pharmaceuticals LP
3 years

A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line

Steven Lentz

Internal Medicine

Novo Nordisk, Inc
3 years

Frontier 4

Steven Lentz

Internal Medicine

Novartis Pharmaceuticals Corporation
3 years

A PHASE 1B, OPEN-LABEL STUDY TO ASSESS THE  SAFETY, EFFICACY, PHARMACOKINETICS, AND  PHARMACODYNAMICS OF ALPN-303 IN SUBJECTS  WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)

Janet Pollard

Radiology

Novartis Pharmaceuticals Corporation
3 years

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate

Erin Shriver

Opthalmology

Viridian Therapeutics, Inc
3 years

A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN-001, A Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)

March 2023

New Federal Awards:

Top of Page

Zuhair Ballas

Internal Medicine

NIH S10
1 year       

Full Spectrum Cell Sorter Flow Cytometer

Maya Evans

Psychiatry

NIH F21
1 year

Cellular and molecular investigations of striatal enlargement
in prenatal stress model of neurodevelopmental risk

Marlan Hansen, Contact PI
Patricia Winokur, MPI

Otolarygology,
Internal Medicine

NIH UM1 
7 years

University of Iowa Institute for Clinical and Translational
Science

Robert Roghair

Pediatrics

NIH T35
5 years

Medical Student Summer Research Program

Maria Spies, Contact PI
Michael Spies, MPI

Biochemistry & Molecular
Biology, PSET

NIH R21
2 years

Natural products inhibitors targeting homology-directed DNA
repair for cancer therapy

Stefan Strack

Neuroscience,
Pharmacology

NIH R21
2 years

Interplay between tau and PKA condensates in ADRD

Seth Tomchik

NIH R01
5 years

Mechanisms of compartmentalized plasticity in learning and memory

Competitive Awards:

David Gordon

Pediatrics

NIH R37
2 years

Gene expression signature based screening in Ewing sarcoma

Jia Luo

Pathology

NIH R01
5 years

Endoplasmic Reticulum Stress and Alcohol neurotoxicity

David Weiss, Contact PI
Regina McGrane, MPI

Mirobiology

NSF
3 years

REU Site: Microbiology at the host-pathogen interface

Other Awards:

John Bernat

Pediatrics

Sanofi US Services, Inc
3 years

A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Double-Dummy, Active-Comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients with Gaucher Disease Type 3 (GD3) Who have Reached Therapeutic Goals w

Muhammad Furqan

Internal Medicine

Immunocore Limited
3 years

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

Katherine Mathews

Pediatrics

Virginia Commonwealth University
3 years

GRASP-01-002- Defining Clinical Endpoints in Becker Muscular Dystrophy

Praveen Vikas

Internal Medicine

Pharmaceutical Research Associates
3 years

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in

Daniel Berg

Internal Medicine

Astellas Pharma Global Development, Inc
3 years

A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Panc

Tomohiro Tanaka

Internal Medicine

PPD Investigator Services, LLC
3 years

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis

Alejandro Comellas Freymond

Internal Medicine

AstraZenica AB
3 years

A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA).

Antonio Sanchez

Internal Medicine

Zydus Therapeutics Inc
3 years

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis

Andrea Swenson

Neurology

Massachusetts General Hospital
3 years

HEALEY ALS Platform Trial, Task # 11

Steven Polyak

Internal Medicine

TriNetX
2 years

A Retrospective Observational Study of the Standard of Care, and Medical and Surgical Treatment Patterns in Crohn's Perianal Fistulas (CPF) in the U.S.

February 2023

New Federal Awards:

Top of Page

Ernesto Fuentes

Biochemistry

NIH R01
5 years

Molecular Mechanisms Regulating Bacterial Two-component Signaling Systems

Kristin Claflin

Neuroscience & Pharmacology

NIH K01
5 years

Regulation of neuronal function by mitochondrial uncoupling

Georgina Aldridge

Neurology

NIH R01
5 years

Cortical Alpha-Synuclein in Dementia

Markus Kuehn

Ophthalmology

NIH R01
4 years

T-cell mediated RGC damage in glaucoma

Damian Krysan

Pediatrics

NIH R21
2 years

Systematic Genetic Analysis of C. albicans CNS Infection

Competitive Awards

Noah Butler

Microbiology

NIH R01
5 years

Development and function of CD4+ memory T cells during malaria

Noah Butler

Microbiology

NIH R01
5 years

Regulation of Plasmodium-specific CD4+ T cells

Richard Smith - Contact PI
Carla Nester - MPI
Patrick Breheny - MPI

Otolaryngology, Pediatrics,
and Biostatistics

NIH R01
5 years

C3 Glomerulopathy - A Collaborative Study

Alexander Bassuk

Pediatrics

NIH K12
5 years

Molecular and Cellular Research to Advance Child Health

Other Awards

Ferhaan Ahmad

Internal Medicine

Cytokinetics, Inc
3 years

SEQUOIA-HCM OLE

Stephan Arndt

Psychiatry

Northeast Iowa Behavioral Health
4 years

Evaluation project: Certified Community Behavioral Health Clinic Planning, Development, and Implementation Grant (CCBHC)

John Bernat

Pediatrics

AVROBIO, Inc
3 years

A Follow-Up Study of Subjects with Type 1 Gaucher Disease Who Previously Received AVR-RD-02

Linda Cadaret

Internal Medicine

Acceleron Pharma, Inc
3 years

SOTERIA: An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

Chandrikha Chandrasekharan

Internal Medince

CG Pharmaceuticals, Inc
3 years

A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemoth

Rami El Abiad

Internal Medince

AstraZenica Pharmaceuticals LP
3 years

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis

Umar Farooq

Internal Medince

PRA Health Sciences
3 years

Long-term Follow-up Protocol for Subjects Treated with Adicet Allogeneic Gamma Delta () CAR T Cell Investigational Products

Asad Javed

Internal Medince

Replimune, Inc
3 years

An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination with PD-1 Blockade in Patients with Solid Tumors

Douglas Laux

Internal Medince

Incyte Biosciences Internal S.a.r.l.
3 years

A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS  1) Recurrent/Metastatic Squamous Cell Carci

Margarida Magalhaes-Silverman

Internal Medince

Equillium, Inc.
3 years

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease

Varun Monga

Internal Medince

Medpace Clinical Research, LLC
3 years

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Lama Noureddine

Internal Medince

Otsuka Pharmaceutical Development & Commercialization, Inc.
3 years

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate  the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with  Immunoglobulin A Nephropathy Trial of Sibeprenlimab in the Treatment of Immunogl

Stefan Strack, Contact PI
Marie Gaine, MPI

Neuroscience & Pharmacology

Eagles Autism Foundation
2 years

Primary PKA Dysregulation in Marbach-Schaaf Neurodevelopmental Syndrome

Patricia Winokur

Internal Medince

Pfizer, Inc.
3 years

A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS

January 2023

New Federal Awards:

Top of Page

Bao Vu

Molecular Physiology & Biophysics

NIH R21
2 Years         

Functional and transcriptome analyses of protein kinases in Candida glabrata antifungal drug resistance

Brandon Davies

Biochemistry & Molecular Biology

NIH R01
5 Years

Regulation of Endothelial Lipase and HDL Metabolism by ANGPTL3

Chris Ahern, Contact PI
Barry London, MPI

Molecular Physiology & Biophysics

NIH R01
4 Years

A Versatile Chemical-Genetic Approach to Determine Bases for Arrhythmogenesis and Sodium Channelopathies

Chris Ahern

Molecular Physiology & Biophysics

NIH R35
5 Years

Chemical Biology of Voltage-Gated Cation Channels

David Stoltz

Internal Medicine

NIH T32
5 Years

Climate Change and Lung Health Training Program

Enrique Leira, Contact PI
Anil Chauhan, MPI

Neurology & Internal Medicine

NIH U01
3 Years

The University of Iowa Stroke Preclinical Assessment Network to Support Translational Studies for Acute Cerebroprotection

Kevin Legge

Pathology

NIH R01
5 Years

Protection and Immunity after Polyanhydride Nanoparticle Vaccination against Avian Influenza A Virus

M Washington

Biochemistry & Molecular Biology

NIH R35
5 Years

Structural and mechanistic studies of DNA bypass pathways in eukaryotes

Nikolai Artemyev

Molecular Physiology & Biophysics

NIH R01
4 Years

Molecular underpinnings of photoreceptor transcriptional regulation by CRX and NRL

Santiago Ortega Gutierrez

Neurology

NIH R03
2 Years

Novel risk stratification score for patients with acute Cerebral Venous Thrombosis

Other Awards: 

Brian Link

Internal Medicine

Mayo Clinic (Prime: Genetech)
3 Years

Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) at Least Two Prior Lines of Systemic Therapy and Treated at Cancer Centers Within the LEO Cohort

Chandrikha Chandrasekharan

Internal Medicine

Pfitzer, Inc
3 Years

A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07265028 IN PARTICIPANTS

Christopher Strouse

Internal Medicine

ICON Clinical Research, LLC (Prime: Takeda)
3 Years

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients with Multiple Myeloma

Douglas Hornick

Internal Medicine

AN2 Therapeutics
3 Years

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease

Frank Faraci

Internal Medicine

LeDucq Foundation
5 Years

Brain Endothelium: A Nexus for Cerebral Small Vessel Disease

Grerk Sutamtewagul

Internal Medicine

Pharmaceutical Research Associates (Prime: Gilead Sciences)
3 Years

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study  Evaluating the Safety and Efficacy of Magrolimab versus Placebo in  Combination with Venetoclax and Azacitidine in Newly Diagnosed,  Previously Untreated Patients with Acute Myeloid Leukemia

Jon Houtman

Cancer Center

American Cancer Society
3 Years

Iowa Cancer Research Experience (ICARE)

Katherine Mathews

Pediatrics

Asklepios BioPharmaceutical, Inc.
3 Years

A two-part multicenter study: a randomized, double-blind, placebo-controlled dose-escalation safety and bioavailability phase (Part 1) followed by double-blind, placebo-controlled, adaptive phase (Part 2) study to evaluate the safety and efficacy of LION-

Katherine Mathews

Pediatrics

Lexeo Theraputics
6 Years

A Phase 1/2 Study of the Safety and Efficacy of LX-2006 Gene Therapy in Friedreich's Ataxia

Michael Ohl

Internal Medicine

Iowa Department of Public Health (Prime: SAMHSA)
1 Year

The Integrated Addiction Care Coordination and Essential Support Services (iACCESS)

Muhammad Furqan

Internal Medicine

Amgen, Inc.
3 Years

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Rami El Abiad

Internal Medicine

Celgene International II SARL LC
3 Years

A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS

Saima Sharif

Internal Medicine

GlaxoSmithKline LLC
9 Years

Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers

Seth Tomchik

Neurosciences & Pharmacology

Texas A&M University (Prime: NIH)
2 Years

The role of Nf1 in sleep-dependent regulation of metabolic function

Umar Farooq

Internal Medicine

Caribou Biosciences, Inc.
3 Years

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Varun Monga

Internal Medicine

C4 Therapeutics, Inc.
3 Years

Phase1/2 open-label multicenter study to characterize the safety and tolerability of CFT8634 in subjects with locally Advanced or Metastatic SMARCB1 perturbed cancers Including Synovial Sarcoma and SMARCB1-Deleted Solid Tumors

Xingshen Sun

Anatomy & Cell Biology

Cystic Fibrosis Foundation
3 Years

004590G222 Early life impact of CFTR modulators on the endocrine pancreas and diabetes in CF

Top of Page